Molecular Partners to present at the Jefferies 2015 Global Healthcare Conference (New York) Freitag, 22. Mai 2015 - 21:15
 | ||||||||||||||
| Press release (PDF) | ||||||||||||||
Molecular Partners to present at the Jefferies 2015 Global Healthcare Conference (New York) | ||||||||||||||
Zurich-Schlieren, May 22, 2015. Molecular Partners AG (ticker: MOLN) today announced that its COO, Dr. Patrick Amstutz, will present at the Jefferies 2015 Global Healthcare Conference (New York) on Monday 01 June 2015 at 03:30 PM Eastern Time (09:30 PM CET).
A copy of the presentation handout will be made available on the company's websitewww.molecularpartners.com, within the Investors section. | ||||||||||||||
About Molecular Partners AG Molecular Partners is a clinical-stage biopharmaceutical company that is developing a new powerful class of therapies known as DARPins™. DARPins™ are potent, specific and versatile small protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin™ technology has the potential to offer a “multi-benefit” approach to treatment, which enables DARPins™ to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins™ have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.
Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Actavis, Roche and Janssen and is backed by established biotech investors. For more information regarding Molecular Partners, go to:www.molecularpartners.com.
For further details please contact:
|